There was grade 3 Neuropathy Tenofovir Viread was relatively rare. In the group of 18 patients died cabazitaxel within 30 days after the last dose of study medication. Neutropenia and its clinical consequences was the hour Common cause of seven of these Todesf Ll attributed. Several factors k Can these results on toxicity t have influenced. A subgroup analysis reported the incidence of neutropenia was significantly more hours Forth in Older M Nnern and lower centers in europe European studies than in North America or other regions. Similarly, the incidence of diarrhea was significantly h Forth in Older patients and patients who previously had radiation therapy. M Possible preventive Ma took Expanded risk reduction in dose to 20 mg/m2 in certain high-risk patients or primary Re prophylaxis with granulocyte-colony stimulating factor and secondary rprophylaxe With growth factors, or dose delay Struggled against the subsequent cycles, or both. An open, randomized Phase III study was to evaluate the inferiority and safety of cabazitaxel 20 mg/m2 25 mg/m2 compared initiated, the results at the end of 2017.31 due Aufkl Tion of patients, the combination of proactive justified by vigilant adherence to established management protocols. In fact, it should be noted that adhere to the Security Council advice to all centers to the American Society of Clinical Oncology S-rules, there were no other adverse events related Todesf Lle in the study TROPIC. remains the only cytotoxic agent cabazitaxel with a significant advantage over mitoxantrone has been implicated in survival when used in combination with prednisone for the treatment of mCRPC that has progressed after treatment with docetaxel. Several studies are underway to evaluate the efficacy and safety of cabazitaxel both alone and in combination with other agents, 12 and a phase III trial comparing the efficacy of cabazitaxel / prednisone as first-line chemotherapy of docetaxel / prednisone Recruiting began in May 2011.32 abiraterone acetate androgen receptor signaling remains for many prostate cancer that progresses despite continued ADT. After medical or surgical castration persistent, though not negligible Ssigbar, low concentrations of androgens from extragonadal sources such as the adrenal glands are produced. Some PROM acquire the F Ability, stero To convert adrenal androgen to activate the maintenance of sufficient level to androgen receptor. The inhibition of androgen production and sustained signaling mediated by the androgen receptor are relevant for therapeutic strategies mCRPC.33 abiraterone acetate, a selective inhibitor of androgen biosynthesis, which is powerful BI skirts cytochrome P450c17. Phase II clinical trials with abiraterone acetate have promising results, 34,35, the best now in a PS-341 randomized, double-blind, controlled CONFIRMS were shown Controlled by placebo phase III trial of abiraterone acetate and low dose prednisone in patients with mCRPC that show after chemotherapy with docetaxel-based 0.36 The results of this Phase III trial, was advanced that patients with abiraterone acetate Plus were low dose prednisone / prednisolone treatment showed significant improvement in overall survival compared to patients treated with prednisone / prednisolone treated with placebo. After a median follow-up of 12.8 months, overall survival was 10.9 months compared.